CY1112184T1 - Πυριδοξαμινη για χρηση στην αγωγη της διαβητικης nεφροπαθειας στο διαβητη τυπου ii - Google Patents

Πυριδοξαμινη για χρηση στην αγωγη της διαβητικης nεφροπαθειας στο διαβητη τυπου ii

Info

Publication number
CY1112184T1
CY1112184T1 CY20111101286T CY111101286T CY1112184T1 CY 1112184 T1 CY1112184 T1 CY 1112184T1 CY 20111101286 T CY20111101286 T CY 20111101286T CY 111101286 T CY111101286 T CY 111101286T CY 1112184 T1 CY1112184 T1 CY 1112184T1
Authority
CY
Cyprus
Prior art keywords
pyridoxamine
diabetes
treatment
type
diabetic nephropathy
Prior art date
Application number
CY20111101286T
Other languages
English (en)
Inventor
Thorsten Degenhardt
Robert Schotzinger
J Wesley Fox
Original Assignee
Nephrogenex, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nephrogenex, Inc. filed Critical Nephrogenex, Inc.
Publication of CY1112184T1 publication Critical patent/CY1112184T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

Η παρούσα εφεύρεση παρέχει φαρμακευτικές συνθέσεις που περιλαμβάνουν μονάδες δόσεως πυριδοξαμίνης, ή ενός φαρμακευτικά αποδεκτού άλατος αυτής· και ένα φαρμακευτικά αποδεκτό φορέα, και μεθόδους για τη χρήση τους στον περιορισμό της εξελίξεως της νεφρικής νόσου και/ή των διαβητικών επιπλοκών σε διαβητικούς ασθενείς.
CY20111101286T 2003-06-20 2011-12-23 Πυριδοξαμινη για χρηση στην αγωγη της διαβητικης nεφροπαθειας στο διαβητη τυπου ii CY1112184T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48003203P 2003-06-20 2003-06-20
US56206204P 2004-04-14 2004-04-14
EP04755763A EP1643999B8 (en) 2003-06-20 2004-06-18 Pyridoxamine for use in the treatment of diabetic nephropathy in type ii diabetes

Publications (1)

Publication Number Publication Date
CY1112184T1 true CY1112184T1 (el) 2015-12-09

Family

ID=33544423

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111101286T CY1112184T1 (el) 2003-06-20 2011-12-23 Πυριδοξαμινη για χρηση στην αγωγη της διαβητικης nεφροπαθειας στο διαβητη τυπου ii

Country Status (10)

Country Link
US (3) US20050014799A1 (el)
EP (1) EP1643999B8 (el)
AT (1) ATE526023T1 (el)
CA (1) CA2529538C (el)
CY (1) CY1112184T1 (el)
DK (1) DK1643999T3 (el)
ES (1) ES2374399T3 (el)
PL (1) PL1643999T3 (el)
PT (1) PT1643999E (el)
WO (1) WO2004112788A1 (el)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750209B1 (en) * 1995-09-12 2004-06-15 Kansas University Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
WO2005077902A2 (en) * 2004-02-09 2005-08-25 Biostratum, Inc. Methods for the synthesis of pyridoxamine
WO2006028007A1 (ja) * 2004-09-06 2006-03-16 Kowa Co., Ltd. 糸球体疾患治療剤
US8158146B2 (en) 2005-09-28 2012-04-17 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
WO2008070778A2 (en) * 2006-12-06 2008-06-12 Nephrogenex Inc. Pyridoxamine and low molecular weight heparinoids for diabetic kidney disease
JP2013526605A (ja) * 2010-05-25 2013-06-24 エリック カーツ， 脂肪酸の安定な処方物
WO2013167991A1 (en) * 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
EP3004049B1 (en) 2013-06-04 2018-09-05 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
NZ736131A (en) 2014-09-26 2019-04-26 Cellix Bio Private Ltd Compositions and methods for the treatment of epilepsy and neurological disorders
CA2967908C (en) 2014-09-29 2020-11-17 Mahesh Kandula Compositions and methods for the treatment of multiple sclerosis
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
CN110845355A (zh) 2015-01-06 2020-02-28 塞尔利克斯生物私人有限公司 用于治疗炎症和疼痛的组合物和方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254572A (en) 1987-11-27 1993-10-19 Vesta Medicines (Pty) Ltd. Method and composition for supplementing vitamin B6 where the PN-PLP pathway is disturbed
US5288716A (en) 1987-02-18 1994-02-22 Ulrich Speck Use of pyridoxine derivatives in the prevention and treatment of hyperlipidaemia and atherosclerosis
US6228858B1 (en) * 1995-09-12 2001-05-08 University Of Kansas Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
US6740668B1 (en) * 1995-08-28 2004-05-25 Kansas University Medical Center Methods for inhibiting diabetic complications
US6716858B1 (en) * 1995-08-28 2004-04-06 Kansas University Medical Center Methods for inhibiting diabetic complications
US6436969B1 (en) * 1995-09-12 2002-08-20 Kansas University Medical Center Research Institute Inc. Dialysis solutions and methods
US5744451A (en) * 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
US6750209B1 (en) * 1995-09-12 2004-06-15 Kansas University Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
US6730686B1 (en) * 1995-09-12 2004-05-04 Kansas University Medical Center Methods for inhibiting oxidative modification of proteins
US20030013746A1 (en) * 1996-09-10 2003-01-16 University Of Kansas Medical Center. Advanced glycation end-product intermediaries and post-amadori inhibition
US7030146B2 (en) * 1996-09-10 2006-04-18 University Of South Carolina Methods for treating diabetic neuropathy
AU762030B2 (en) * 1998-10-22 2003-06-19 Kansas University Medical Center Research Institute, Inc. Methods for inhibiting diabetic complications
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
US6489345B1 (en) * 1999-07-13 2002-12-03 Medicure, Inc. Treatment of diabetes and related pathologies
CA2383252A1 (en) 1999-08-24 2001-03-01 Medicure International Inc. Treatment of cardiovascular related pathologies
EP1341532B1 (en) * 2000-11-02 2006-07-26 University of South Carolina Use of pyridoxamine for the treatment and inhibition of obesity-related complications
US6521645B2 (en) * 2000-11-20 2003-02-18 The University Of Kansas Medical Center Methods for the treatment and prevention of urinary stone disease

Also Published As

Publication number Publication date
EP1643999A1 (en) 2006-04-12
US20060287367A1 (en) 2006-12-21
PT1643999E (pt) 2012-01-09
CA2529538A1 (en) 2004-12-29
ATE526023T1 (de) 2011-10-15
DK1643999T3 (da) 2012-01-02
US20080119525A1 (en) 2008-05-22
WO2004112788A1 (en) 2004-12-29
US8067444B2 (en) 2011-11-29
CA2529538C (en) 2011-04-26
ES2374399T3 (es) 2012-02-16
EP1643999B1 (en) 2011-09-28
US20050014799A1 (en) 2005-01-20
EP1643999B8 (en) 2012-03-14
PL1643999T3 (pl) 2012-02-29

Similar Documents

Publication Publication Date Title
CY1112184T1 (el) Πυριδοξαμινη για χρηση στην αγωγη της διαβητικης nεφροπαθειας στο διαβητη τυπου ii
CY1117656T1 (el) Επιλογες θεραπειας για τη νοσο του fabry
EA200701175A1 (ru) Лекарственные средства, предназначенные для лечения или предупреждения фиброзных заболеваний
MXPA04011612A (es) Uso oftalmologico de roflumilasto para el tratamiento de enfermedades del ojo.
NO20053224D0 (no) Patient controlled drug administration device.
DE60323090D1 (de) 1h-imidazoä4,5-cüchinolinderivate zur behandlung von protein kinase-abhängigen krankheiten
DK1781277T3 (da) Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
RU2011115406A (ru) Новые пиримидиновые производные и их применение в терапии, а также применение пиримидиновых производных в изготовлении лекарственного средства для предупреждения и/или лечения болезни альцгеймера
SG167657A1 (en) Novel medicament compositions based on tiotropium salts and on salmeterol salts
CY1106430T1 (el) Φαρμακα για εισπνοη που πepιλαμβανουν βηταμιμητικα και αντιχολινepγικο
IL175259A0 (en) Use of a deoxynojirimycin derivative or a pharmaceutically salt thereof
HK1068606A1 (en) Novel aminobenzoephenones
TW200637544A (en) Medicaments for the treatment or prevention of fibrotic diseases
NO20034863D0 (no) Deuterert 3-piperidinopropiofenon og medikamenter inneholdende disse
AU2003286726A8 (en) Methods for drug discovery, disease treatment, and diagnosis using metabolomics
HRP20070291T3 (en) Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis
CY1107231T1 (el) Υποκατεστημενα παραγωγα 4-αμινοκυκλοεξανολης
HK1097762A1 (en) Pharmaceutical compositions for the treatment of renal dysfunction, disease or disorder, in particular in diabetic patients
SI1869185T1 (sl) Konjugat ki obsega protein P za zdravljenje raka
IL170519A (en) Use of fenofibrate or pharmaceutically acceptable salt thereof, orlistat and pharmaceutically acceptable carrier in the manufacture of medicaments for the treatment of obesity and pharmaceutical compositions containing them
MXPA02006511A (es) Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido.
MX2009006670A (es) Composicion farmaceutica que usa el aliskiren y el avosentan.
ATE392213T1 (de) Verwendung von gamma-gt inhibitoren zur behandlung von chronischen degenerativerkrankungen
DE602005011029D1 (de) Therapeutisches mittel zur behandlung von plasmazellneoplasien